B Douglas Smith

Professor

1983 …2018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 31 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Leukemia Medicine & Life Sciences
Myelodysplastic Syndromes Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
alvocidib Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1983 2018

A multi-center phase i trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure

Zeidan, A. M., Knaus, H. A., Robinson, T., Towlerton, A. M. H., Warren, E. H., Zeidner, J. F., Blackford, A. L., Duffield, A. S., Rizzieri, D., Frattini, M. G., Levy, Y. M., Schroeder, M. A., Ferguson, A., Sheldon, K. E., Dezern, A., Gojo, I., Gore, S. D., Streicher, H., Luznik, L. & Smith, B. D., Aug 1 2018, In : Clinical Cancer Research. 24, 15, p. 3519-3527 9 p.

Research output: Contribution to journalArticle

Myelodysplastic Syndromes
ipilimumab
Inducible T-Cell Co-Stimulator Protein
Bone Marrow
T-Lymphocytes

Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development

Seo, J., Smith, B. D., Estey, E., Voyard, E., O’ Donoghue, B. & Bridges, J. F. P., Apr 26 2018, (Accepted/In press) In : Current Medical Research and Opinion. p. 1-9 9 p.

Research output: Contribution to journalArticle

Patient Preference
Acute Myeloid Leukemia
Pharmaceutical Preparations
Caregivers
Disease-Free Survival

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., Gojo, I., Gocke, C., Rosner, G., Little, R. F., Wright, J. J., Doyle, L. A., Smith, B. D. & Karp, J., Sep 1 2018, In : Leukemia Research. 72, p. 92-95 4 p.

Research output: Contribution to journalLetter

alvocidib
Mitoxantrone
Daunorubicin
Cytarabine
Acute Myeloid Leukemia

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results

Cortes, J. E., Smith, B. D., Wang, E. S., Merchant, A., Oehler, V. G., Arellano, M., DeAngelo, D. J., Pollyea, D. A., Sekeres, M. A., Robak, T., Ma, W. W., Zeremski, M., Naveed Shaik, M., Douglas Laird, A., O'Connell, A., Chan, G. & Schroeder, M. A., Jan 1 2018, (Accepted/In press) In : American journal of hematology.

Research output: Contribution to journalArticle

Daunorubicin
Myelodysplastic Syndromes
Cytarabine
Acute Myeloid Leukemia
Confidence Intervals

Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients

Robinson, T., Prince, G. T., Thoburn, C., Warlick, E., Ferguson, A., Kasamon, Y. L., Borrello, I. M., Hess, A. & Smith, B. D., Apr 5 2018, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-11 11 p.

Research output: Contribution to journalArticle

Myelodysplastic Syndromes
Granulocyte-Macrophage Colony-Stimulating Factor
Vaccination
Immune System
Homologous Transplantation